Evidence map›Paper›PMID 35711440›Full record

ArticleFrontiers in immunology2022

Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study.

Emilie Gaiffe, Dewi Vernerey, Laurent Bardiaux, Franck Leroux, Aurelia Meurisse, Jamal Bamoulid, Cécile Courivaud, Philippe Saas, Pierre Tiberghien, Didier Ducloux

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Emilie GaiffeBesançon University Hospital, Fédération Hospitalo-Universitaire Integrated Center for REsearch in inflammatory diseASes (FHU INCREASE), Besançon, France.
Dewi VernereyUniv. Bourgogne Franche-Comté, Institut National De La Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Bourgogne Franche-Comté, Unité Mixte De Recherche 1098 (UMR1098), RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Laurent BardiauxÉtablissement Français Du Sang Occitanie, Toulouse, France.
Franck LerouxInstitut National de la santé et de la recherche médicale Centre d'Investigation Clinique (INSERM CIC)-1431, Centre Hospitalier Universitaire Besançon, Besançon, France.
Aurelia MeurisseUniv. Bourgogne Franche-Comté, Institut National De La Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Bourgogne Franche-Comté, Unité Mixte De Recherche 1098 (UMR1098), RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Jamal BamoulidUniv. Bourgogne Franche-Comté, Institut National De La Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Bourgogne Franche-Comté, Unité Mixte De Recherche 1098 (UMR1098), RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Cécile CourivaudUniv. Bourgogne Franche-Comté, Institut National De La Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Bourgogne Franche-Comté, Unité Mixte De Recherche 1098 (UMR1098), RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Philippe SaasUniv. Bourgogne Franche-Comté, Institut National De La Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Bourgogne Franche-Comté, Unité Mixte De Recherche 1098 (UMR1098), RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Pierre TiberghienUniv. Bourgogne Franche-Comté, Institut National De La Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang Bourgogne Franche-Comté, Unité Mixte De Recherche 1098 (UMR1098), RIGHT Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Didier DuclouxBesançon University Hospital, Fédération Hospitalo-Universitaire Integrated Center for REsearch in inflammatory diseASes (FHU INCREASE), Besançon, France.
Inserm · FRÉtablissement Français du Sang · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Red blood cell (RBC) transfusions are frequently required in the early period after kidney transplantation. However, the consequences of RBC transfusions on long-term outcomes are largely unrecognized. Methods: We conducted a nationwide French cohort study involving all 31 French kidney transplant centers. Patients having received a first kidney transplant between January 1, 2002 and December 31, 2008 were identified through the national registry of the French BioMedecine Agency ( Results: Among 12,559 patients included during the study period, 3,483 (28%) were transfused during the first 14 days post-transplant. Median follow-up was 7.6 (7.5-7.8) years. Multivariable analysis determined that post-transplant RBC transfusion was associated with an increased risk in transplant failure (HR 1.650, 95%CI [1.538;1.771] p<0.0001). Both sensitivity and propension score analyses confirmed the previous result. Conclusions: Early red blood cell transfusion after kidney transplantation is associated with increased transplant failure.

Indexed as

Hematopoietic Stem Cell TransplantationKidney TransplantationCohort StudiesErythrocyte TransfusionHumansRegistriesearly transfusiongraft losskidney transplantationred blood celltransplant failure

Identifiers

PMID35711440
PMCPMC9197232
OpenAlexW4282035813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.